… action have been used for COVID-19 patients in clinical trials, … the immunomodulatory drugs
administered to treat COVID-19 or … , the most critical immunomodulatory agents from different …

… with immunomodulatory agents … immunomodulating agents, including neutralizing monoclonal
antibodies, corticosteroids, and other molecules in the management of severe COVID-19, …

… To date, treatment of severe COVID-19 is far from clear. Therefore, it is urgent to develop
an … for the treatment of patients with COVID-19. Most patients with severe COVID-19 exhibit …

… intensity anti-inflammatory and immunomodulatory therapy could be a … immunomodulating
drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs …

… CJT is a principal investigator for two randomised controlled trials investigating angiotensin
II receptor blockers in the treatment of COVID-19 among inpatient and outpatients. NEI is …

… insights into the treatment of COVID-19. Combined use of an immunomodulatory agent – to
… other immunomodulatory agents, such as ulinastatin, for treatment of the cytokine storm for …

… with COVID-19 treated with various immunomodulatory agents. Our study demonstrates
that in assessing whether certain oncologic medications are associated with worse COVID-19 …

… , this review encourages further research into the use of MSCs and/or EVs for treating
COVID-19 after strictly following appropriate manufacturing procedures, quality control …

… of the immunomodulatory drugs used to manage COVID-19. A … the efficacy of the
immunomodulatory agents, including … , and blood-purification therapy, in COVID-19 patients. The …

… of potent pharmacological treatments for COVID-19. In most of the contracted patients, …
other immunomodulatory drugs, was associated with a lower rate of hospital admission for …